Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines
Hematological Oncology · 2026
DOI: 10.1002/hon.70228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Marina Pérez-Aguilera und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Gene Expression Profiling, Transcriptome, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Consejería de Educación, Ciencia y Universidades, Ministerio de Ciencia, Innovación y Universidades (MICIU)/Agencia Estatal de Investigación (AEI).
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is the most prevalent form of non‐Hodgkin lymphoma, exhibiting significant molecular and clinical heterogeneity. Advances in classification integrating phenotypic, genetic, and transcriptomic features have improved diagnosis and prognosis. However, a comprehensive and integrated molecular characterization of DLBCL cell lines is still lacking, which limits their optimal use as reliable experimental models. We employed fluorescence in situ hybridization, immunohistochemistry, and targeted DNA and RNA sequencing to identify genetic subtypes and determine the cell of origin, providing a comprehensive characterization of 29 DLBCL cell lines through the integration of phenotypic, genomic, and transcriptomic data. Principal component analysis, gene set enrichment analysis (GSEA), differential expression profiling, and regulon analysis enabled us to dissect molecular heterogeneity. We achieved high concordance in genetic subtype assignment using multiple classification algorithms (2‐S, LymphGen, and DLBclass). The DHIT/DZ signature and transcriptional profiling further revealed additional molecular complexity. Some DLBCL‐NOS cases exhibited high‐grade features, suggesting that gene expression signatures may capture biological aggressiveness better than cytogenetic methods. GSEA confirmed the relevance of signaling pathways across DLBCL subtypes, and regulatory network analysis identified specific transcription‐factor activities that support these pathways. MCD cell lines showed increased NF‐κB and STAT signaling, while EZB/MYC+ cell lines demonstrated increased proliferation and cell cycle regulation, along with decreased NF‐κB/STAT activity. Our study offers a detailed molecular overview of DLBCL cell lines, underscoring their relevance for mechanistic and therapeutic research. The data highlights how integrating genetic and transcriptomic analyses can refine disease classification and guide personalized therapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Lymphoma Research Group, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain.
- Immune System Development and Function Department, Metabolism in Cancer and Aging Research Group, Centro de Biologia Molecular Severo Ochoa (CBM), CSIC-Universidad Autonoma de Madrid, Madrid, Spain.
- Bioinformatics Unit, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain.
- Pathology Department, Cancer Molecular Pathology Group, Hospital Puerta de Hierro-Majadahonda, IDIPHISA, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
- Monoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
ORCID-Profile: Ana Ortega-Molina, Margarita Sánchez-Beato
Förderung
- Instituto de Salud Carlos III
- Consejería de Educación, Ciencia y Universidades
- Ministerio de Ciencia, Innovación y Universidades (MICIU)/Agencia Estatal de Investigación (AEI)
- Fundación Cientifíca Asociacion Española Contra el Cáncer (FCAECC)
- Consejo Superior de Investigaciones Cientifícas
- Fundación Fero
- Fundación BBVA
- Fundación para la Investigación Biomédica H. U. Puerta de Hierro-Majadahonda (FIBHUPHM)
Zitieren
APA
Pérez-Aguilera, M., Pedrosa, L., Gómez, S., Salazar-Ortego, S., Fernández-Miranda, I., Muñoz-Viana, R., Martín-Acosta, P., Martín-Lunas, B. L., Jimeno, R., Yanguas-Casás, N., Horcajo, B., Roncador, G., Martínez-Climent, J. A., Ortega-Molina, A., & Sánchez-Beato, M. (2026). Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines. Hematological Oncology. https://doi.org/10.1002/hon.70228
Vancouver
Pérez-Aguilera M, Pedrosa L, Gómez S, Salazar-Ortego S, Fernández-Miranda I, Muñoz-Viana R, et al. Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines. Hematological Oncology. 2026. doi:10.1002/hon.70228
BibTeX
@article{PrezAguilera2026,
author = {Pérez-Aguilera, Marina and Pedrosa, Lucía and Gómez, Sagrario and Salazar-Ortego, Sara and Fernández-Miranda, Ismael and Muñoz-Viana, Rafael and Martín-Acosta, Paloma and Martín-Lunas, Beatriz L and Jimeno, Rebeca and Yanguas-Casás, Natalia and Horcajo, Beatriz and Roncador, Giovana and Martínez-Climent, José A and Ortega-Molina, Ana and Sánchez-Beato, Margarita},
title = {Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70228}
}
EUVIMED